A Phase 1 Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, Drug-Drug Interactions, and Pharmacokinetics of TBD11

Inclusion Criteria: * 18 to 55 years of age, inclusive. * Healthy, as determined by the Investigator through medical history and clinical examination before enrolment. * Able to understand and comply with trial and site procedures, understand study risks, and provide written informed consent before any trial-specific procedure. * Able to complete all Screening evaluations and remain in the clinical research facility for required inpatient periods. * BMI between 18 and 32 kg/m², inclusive, and body weight of at least 50 kg at Screening. * Resting vital signs within protocol-defined ranges at Screening and Day -1. * 12-lead ECG consistent with normal cardiac conduction and function at Screening. * Non-smoker within the previous 90 days, with negative urine cotinine at Screening and no use of tobacco- or nicotine-containing products. * Screening clinical chemistry, coagulation, complete blood count, and urinalysis within laboratory reference ranges, unless assessed as not clinically significant by the Investigator/designee. * Negative HBsAg and HCV antibody at Screening. * Negative IGRA test for TB infection. * Negative HIV antibody test at Screening. * Negative urine drug screen and urine alcohol screen at Screening and Day -1. * For participants assigned female sex at birth: negative urine and serum pregnancy tests at Screening and non-childbearing potential as defined in the protocol. * For participants assigned male sex at birth who are not sterilized and sexually active with a female partner of childbearing potential: agreement to use condoms from Day -1 through 90 days after the last dose and not donate sperm during the trial and for 90 days after the last dose. Exclusion Criteria: * Current or past clinically significant cardiovascular, cerebrovascular, respiratory, gastrointestinal, haematologic, renal, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic, psychiatric, or other major disease. * Current or past condition expected to require treatment during the trial with medication known to inhibit or induce CYP3A4. * Clinically relevant cardiovascular disorder or symptoms suggestive of such disorder. * Prior history of TB infection or TB disease. * Current cough lasting more than 2 weeks, fever, night sweats, or unexplained weight loss. * Close household or repeated living/workspace contact with an individual with active TB in the preceding 12 months. * Active malignancy within 5 years of Screening, except basal cell or squamous cell skin cancers; any history of breast cancer or melanoma is exclusionary. * History of drug abuse within 1 year before Screening or use of specified hard drugs within 1 year before Screening, unless limited to prescribed opioid or amphetamine medication not currently being taken. * Surgical or medical condition that may alter absorption, metabolism, or excretion of trial treatment. * Use of prohibited medications, vitamins, dietary supplements, herbal products, or vaccination within the protocol-defined windows. * Contraindication to trial interventions or excipients, or clinically significant allergic/anaphylactic reaction to any medication. * Participation in another investigational drug, vaccine, or device study within 30 days or 5 half-lives, whichever is longer, before Screening and during this trial. * Any condition that may interfere with informed consent, compliance, interpretation of results, or place the participant at undue risk. * Blood donation within 2 months before Screening or planned blood donation during the trial or within 12 weeks after the final visit.